Compare CLFD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | EYPT |
|---|---|---|
| Founded | 1979 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Utilities | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 419.9M |
| IPO Year | 1995 | 2005 |
| Metric | CLFD | EYPT |
|---|---|---|
| Price | $31.83 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $43.50 | $31.80 |
| AVG Volume (30 Days) | 136.2K | ★ 3.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $85,034,000.00 | $7,539,000.00 |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $22.30 | $3,115.57 |
| P/E Ratio | $220.57 | ★ N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.76 | $3.42 |
| 52 Week High | $52.73 | $19.11 |
| Indicator | CLFD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 34.65 |
| Support Level | $27.95 | $3.95 |
| Resistance Level | $33.27 | $14.72 |
| Average True Range (ATR) | 0.89 | 0.32 |
| MACD | 0.35 | 0.26 |
| Stochastic Oscillator | 89.28 | 47.67 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.